Aequus Pharmaceuticals Current Valuation vs. Shares Owned By Insiders

AQSZF Stock  USD 0.01  0  18.18%   
Based on Aequus Pharmaceuticals' profitability indicators, Aequus Pharmaceuticals may not be well positioned to generate adequate gross income at the moment. It has a very high risk of underperforming in January. Profitability indicators assess Aequus Pharmaceuticals' ability to earn profits and add value for shareholders.
For Aequus Pharmaceuticals profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Aequus Pharmaceuticals to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Aequus Pharmaceuticals utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Aequus Pharmaceuticals's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Aequus Pharmaceuticals over time as well as its relative position and ranking within its peers.
  
Check out Trending Equities.
Please note, there is a significant difference between Aequus Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Aequus Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aequus Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Aequus Pharmaceuticals Shares Owned By Insiders vs. Current Valuation Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Aequus Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Aequus Pharmaceuticals value to that of its competitors to determine the firm's financial worth.
Aequus Pharmaceuticals is rated second in current valuation category among its peers. It is number one stock in shares owned by insiders category among its peers . The ratio of Current Valuation to Shares Owned By Insiders for Aequus Pharmaceuticals is about  202,411 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Aequus Pharmaceuticals' earnings, one of the primary drivers of an investment's value.

Aequus Current Valuation vs. Competition

Aequus Pharmaceuticals is rated second in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Health Care industry is presently estimated at about 4.71 Billion. Aequus Pharmaceuticals adds roughly 3.03 Million in current valuation claiming only tiny portion of equities under Health Care industry.

Aequus Shares Owned By Insiders vs. Current Valuation

Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.

Aequus Pharmaceuticals

Enterprise Value

 = 

Market Cap + Debt

-

Cash

 = 
3.03 M
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.

Aequus Pharmaceuticals

Insiders Shares

 = 

Executives Shares

+

Employees

 = 
14.96 %
Although the research on effects of insider trading on prices and volatility is still relatively inconclusive, and investors are advised to pay close attention to the distribution of equities among company's stakeholders to avoid many problems associated with the disclosure of price-sensitive information.

Aequus Shares Owned By Insiders Comparison

Aequus Pharmaceuticals is currently under evaluation in shares owned by insiders category among its peers.

Aequus Pharmaceuticals Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Aequus Pharmaceuticals, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Aequus Pharmaceuticals will eventually generate negative long term returns. The profitability progress is the general direction of Aequus Pharmaceuticals' change in net profit over the period of time. It can combine multiple indicators of Aequus Pharmaceuticals, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Aequus Pharmaceuticals Inc., a specialty pharmaceutical company, develops and commercializes drugs in Canada. Aequus Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in Vancouver, Canada. Aequus Pharmaceuticals operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. It employs 14 people.

Aequus Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Aequus Pharmaceuticals. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Aequus Pharmaceuticals position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Aequus Pharmaceuticals' important profitability drivers and their relationship over time.

Use Aequus Pharmaceuticals in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Aequus Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Aequus Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Aequus Pharmaceuticals Pair Trading

Aequus Pharmaceuticals Pair Trading Analysis

The ability to find closely correlated positions to Aequus Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Aequus Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Aequus Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Aequus Pharmaceuticals to buy it.
The correlation of Aequus Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Aequus Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Aequus Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Aequus Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Aequus Pharmaceuticals position

In addition to having Aequus Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run SPAC Thematic Idea Now

SPAC
SPAC Theme
Entities that are involved in raising capital, merging with and acquiring companies, and investing in private equity through leveraged buyouts. The SPAC theme has 25 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize SPAC Theme or any other thematic opportunities.
View All  Next Launch

Other Information on Investing in Aequus OTC Stock

To fully project Aequus Pharmaceuticals' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Aequus Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Aequus Pharmaceuticals' income statement, its balance sheet, and the statement of cash flows.
Potential Aequus Pharmaceuticals investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although Aequus Pharmaceuticals investors may work on each financial statement separately, they are all related. The changes in Aequus Pharmaceuticals's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Aequus Pharmaceuticals's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.